Publication | Closed Access

Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1–2 study

Hematological MalignancyMedicineHematologyPathologyHigh-risk Myelodysplastic SyndromesPharmacotherapyOncologyPhase 1Phase 1–2Myeloid Neoplasia